WINTON GROUP Ltd Takes Position in NewAmsterdam Pharma Company N.V. $NAMS

WINTON GROUP Ltd bought a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 28,665 shares of the company’s stock, valued at approximately $1,006,000.

Other hedge funds have also bought and sold shares of the company. Farther Finance Advisors LLC boosted its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares in the last quarter. Navalign LLC bought a new stake in NewAmsterdam Pharma during the fourth quarter worth about $46,000. NBC Securities Inc. bought a new stake in NewAmsterdam Pharma during the fourth quarter worth about $86,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in NewAmsterdam Pharma by 26.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock worth $193,000 after acquiring an additional 1,156 shares in the last quarter. Finally, Simon Quick Advisors LLC bought a new stake in NewAmsterdam Pharma during the fourth quarter worth about $202,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $30.38 on Wednesday. The stock has a market capitalization of $3.55 billion, a PE ratio of -16.97 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 52-week low of $17.63 and a 52-week high of $42.21. The company has a 50-day simple moving average of $33.53 and a two-hundred day simple moving average of $33.82.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The firm had revenue of $3.04 million during the quarter. As a group, equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.74% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on NAMS shares. Needham & Company LLC boosted their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial began coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $48.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.